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Evaluation of multiplex tandem PCR (MT-PCR) assays for the detection of 
bacterial resistance genes among Enterobacteriaceae in clinical urines 
K. Schmidt1*, K. K. Stanley2, R. Hale2, L. Smith2, J. Wain1,3, J. O’Grady1,3 and D. M. Livermore1,4  
Abstract 
Background: Increasing resistance drives empirical use of less potent and previously reserved antibiotics, including for urinary 
tract infections (UTIs). Molecular profiling, without culture, might better guide early therapy. 
Objectives: To explore the potential of AusDiagnostics multiplex tandem (MT) PCR UTI assays. 
Methods: Two MT-PCR assays were developed successively, seeking 8 or 16 resistance genes. Amplification was tracked 
in real time, with melting temperatures used to confirm product identity. Assays were variously performed on: (i) extracted 
DNA; (ii) cultured bacteria; (iii) urine spiked with reference strains; and (iv) bacteria harvested from clinical urines. Results 
were compared with those from sequencing, real-time SybrGreen PCR or phenotypic susceptibility. 
Results: Performance was similar irrespective of whether DNA, cultures or urines were used, with .90% sensitivity and 
specificity with respect to common b-lactamases, dfr genes and aminoglycoside resistance determinants except 
aadA1/A2/A3, for which carriage correlated poorly with streptomycin resistance. Fluoroquinolonesusceptible and -resistant 
Escherichia coli (but not other species) were distinguished by the melting temperatures of their gyrA PCR products. The 
time from urine to results was ,3 h. 
Conclusions: The MT-PCR assays rapidly identified resistance genes from Gram-negative bacteria in urines as well as from 
cultivated bacteria. Used directly on urines, this assay has the potential to guide early therapy. 
Introduction 
Emergency hospital admissions of elderly UK patients for complicated 
urinary tract infections (cUTIs) doubled from 2002 to 2012.1 These 
infections are the source of most septic episodes with Escherichia coli, 
which is now the most common agent of bacteraemias.2 As elsewhere in 
the world, the spread of MDR E. coli, often of ST131, complicates 
treatment and drives the wider use of previously reserved antibiotics, 
including carbapenems. Meanwhile, increasing trimethoprim resistance 
in the community has led to a switch to nitrofurantoin for the treatment 
of uncomplicated cystitis,3 despite nitrofurantoin having poorer 
pharmacodynamics, tolerability and (for ascending infection) efficacy. 
A potential way to overcome these problems is to move from 
empirical to early targeted therapy, by profiling resistance directly from 
clinical samples, without culture. This can be comprehensively achieved 
by metagenomic sequencing,4 although there is scepticism around 
implementation, based on cost and workflows.5 PCR methods are more 
immediately deployable, cost less, and have been widely adopted to seek 
mecA or carbapenemase genes, informing infection control.6,7 PCR is 
less commonly used to guide treatment, except for rifampicin in the case 
of tuberculosis,8 but its potential is clear. Accordingly, we evaluated two 
multiplex tandem PCR (MT-PCR) panels, seeking common resistance 
genes in Enterobacteriaceae. These were applied to both urines and 
cultivated isolates. The prototype panel sought eight resistance genes 
commonly responsible for resistance to trimethoprim, aminoglycosides 
and fluoroquinolones. The second panel also sought important b-
lactamase genes. 
MT-PCR has two stages. In the first step, samples are amplified in a 
multiplex PCR with primers for all targets in the panel. This is allowed 
to proceed for only 10–18 cycles and, because very little dNTP is thereby 
consumed, each PCR is independent of all others, preserving the relative 
quantification of each target. The Step 1 products are then diluted and 
divided into individual real-time PCR reactions, one for each target. The 
Step 2 reactions use primers 
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7 gyrA (including gyrA/Sa, gyrA/Ra, gyrKlebR/Sb) DNA gyrase (Ser83 and Asp87) fluoroquinolone (ciprofloxacin) 
8 KPparCc topoisomerase IV (Ser80) fluoroquinolone (ciprofloxacin) 
 SPIKE internal control  
 
a This assay was designed to detect point mutations in gyrA affecting Ser83 and Asp87 and associated with high-level ciprofloxacin 
resistance; these were distinguished by PCR products with different Tm values for E. coli only. 
b This assay was designed to identify Klebsiella spp. but not discriminate between resistant and susceptible types. 
c 
This assay was designed to identify fluoroquinolone-resistant/-susceptible Klebsiella spp. based on PCR product Tm. 
nested inside the Step 1 primers, preventing further amplification of any 
non-specific products from Step 1. MT-PCR can thus amplify many 
targets simultaneously, whilst preserving their relative quantities.9 
Materials and methods 
AusDiagnostics assays 
MT-PCR was performed using two sequentially developed research panels 
(AusDiagnostics, Sydney, Australia): (i) an 8-plex (catalogue number 17412) to 
seek eight genes involved in resistance to trimethoprim, aminoglycosides and 
fluoroquinolones (Table 1); and (ii) a 16-plex (catalogue number 2741201) 
additionally seeking b-lactamase gene targets (Table 2). 
Sample processing for MT-PCR assays 
Tests were performed on extracted DNA from 7 reference strains, 42 overnight 
bacterial cultures from CLED Agar (Becton Dickinson, Oxford, UK), 5 urines 
from a healthy volunteer spiked with 108cfu/mL of reference strains from 
overnight broth cultures and 76 clinical urines from the Norfolk and Norwich 
University Hospital (NNUH). 
 Purified DNA was extracted from reference E. coli and 
Klebsiella pneumoniae grown on CLED Agar (Becton Dickinson). Harvested 
bacteria were suspended in a mixture of 200lL of lysis buffer (Roche, Basel, 
Switzerland), 180lL of PBS (Sigma–Aldrich) and 20lL of proteinase K (20 
mg/mL) (Roche) and incubated for 10 min at 65C. DNA was then extracted using 
the MagNA Pure Compact Nucleic Acid Isolation Kit (Roche) with the DNA 
Bacteria v3_2 protocol. 
Bacterial colonies were picked from agar, suspended in 300 lL of water and 
denatured at 95C for 4 min. The suspensions were then diluted 10fold in water, 
with 10lL volumes used for MT-PCR. 
In the case of spiked and clinical urines, 1–1.5mL volumes were first 
centrifuged for 2 min at 300g to remove human cells. The supernatants were then 
centrifuged for 5 min at 12500g to pellet the bacteria, which were thereafter 
treated as for bacterial isolates, as described above. 
Data analysis for MT-PCR 
Data analysis was performed automatically using the integrated MT-Plex Result 
software (AusDiagnostics) for samples meeting the criteria of: (i) a cycle 
threshold (CT), in the second PCR, ,20; and (ii) a correct melting temperature 
(Tm) for the amplified gene. For the 16-plex panel only we added a further 
criterion (iii) of detection of .1000 Step 2 PCR product copies. Quantitative 
analysis of the Step 2 PCR product was performed by comparison with an internal 
control (SPIKE) containing 10000 copies of a synthetic oligonucleotide template 
with corresponding primers. 
Reference methods 
Results from the MT-PCR assays were variously compared with phenotypic 
susceptibility data, SybrGreen real-time PCR for the corresponding gene, or with 
WGS data, determined as below. 
Phenotypic characterization 
Isolates were grown on CLED Agar (Becton Dickinson) at 37C overnight. 
Species were identified by MALDI-TOF (Bru¨ker Daltonics), with susceptibility 
testing performed by BSAC disc diffusion.10 
Molecular characterization 
Extracted DNA was used for WGS on MinION or Illumina instruments, as 
described.4 Alternatively, SybrGreen real-time PCR, with appropriate primers 
(Table 3) and a LightCycler 480 (Roche) were used to seek b-lactamase genes. A 
single colony from overnight culture was resuspended in 100lL of water, 
denatured at 95C for 4 min and used as a template (2lL). The PCR programme 
comprised denaturation at 95C for 5 min, followed by 35 cycles of denaturation 
at 95C for 20s, annealing at 60C for 20s and primer extension at 72C for 30s. 
After the last cycle, the melting curve analysis was followed by denaturation at 
95C, then cooling to 72C. Fluorescence signals were collected continuously at k 
530nm from 72C to 99C at 0.2C/s. 
Ethics 
Ethics approval was not required, because tests were performed, as method 
development, on excess samples submitted to the NNUH clinical microbiology 
laboratory. No patient data were collected. 
Results 
Resistance genes were readily detectable by both the 8- and 16-plex 
assays (Tables 4 and 5 respectively), regardless of whether extracted 
DNA, cultured bacteria or bacteria harvested from urine were used. 
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Table 3. Primers used for the SybrGreen real-time PCR assays seeking b-
lactamase genes 
Primer 
Primer sequence 
(50–30) 
GenBank 
Product 
size (bp) 
TEM_F 
TEM_R 
CAGCGGTAAGATCCTTGAGAG 
GAGTTACATGATCCCCCATGTT KU376497.1 326 
SHV_F 
SHV_R 
CGCCTGTGTATTATCTCCCTGT 
CAAGGTGTTTTTCGCTGACC 
EU586041.1 316 
CMY_F 
CMY_R 
GAGTTACGAAGAGGCAATGACC 
CCAGCCTAATCCCTGGTACATA 
GQ351345.1 310 
OXA1_F 
OXA1_R 
AGACGTGGATGCAATTTTCTGT 
GCACCAGTTTTCCCATACAGTT 
J02967.2 319 
CTX-M gr1_F 
CTX-M gr1_R 
GCAAAAACTTGCCGAATTAGAG 
GCTTATTCATCGCCACGTTATC 
AJ549244.1 320 
CTX-M gr9_F 
CTX-M gr9_R 
CTTTCCAATGTGCAGTACCAGT 
CGGTATTCAGCGTAGGTTCAG 
AF252623.2 320 
8-Plex panel 
The initial 8-plex panel sought common trimethoprim and 
aminoglycoside resistance determinants as well as mutations associated 
with fluoroquinolone resistance. It was applied to 21 samples, including 
7 extracted DNAs, 7 bacterial isolates and 7 urines (2 clinical and 5 
spiked with known bacteria). Water was used as negative control. A total 
of 15 different isolates (9 E. coli and 6 K. pneumoniae), all trimethoprim 
resistant, were represented across the various formats. Trimethoprim 
determinants (dfrA1/A5/A7 or A12) were found in all 21 samples (100% 
sensitivity), consistent with universal phenotypic trimethoprim 
resistance. WGS for 12 organisms, representing 18 samples, confirmed 
the presence of the same dfr genes as found by the MT-PCR assay. 
aac(60)-Ib was detected in 14/21 examined samples and agreed with 
observed tobramycin resistance and sequencing in the 13 cases in which 
this was performed, with 100% sensitivity and specificity. Streptomycin 
adenyltransferase aadA1/A2/A3 genes were found by MT-PCR in 8/21 
analysed samples, including 5/14 streptomycin-resistant isolates but also 
3/7 streptomycinsusceptible isolates, with 35.7% sensitivity and 57.1% 
Table 2. Target genes sought by the 16-plex panel 
Target gene Alleles sought 
 
b-Lactamases 
1 blaTEM including 1, 3, 10, 104–106, 71, 76–84, 138, 143, 150, 155 
2 blaSHV including 1, 2, 5, 11, 12, 25, 26, 38, 56 
3 blaCTX-M group 1 including 1, 3, 15, 28, 29, 32, 36, 58, 79, 103 
4 blaCTX-M group 9 including 9, 13, 14, 24, 27, 38 
5 blaCMY including 2, 4, 16, 31, 73, combined with assay to detect CMY-1 
6 blaOXA-1 including 1, A1, 4, 30 
7 blaOXA-48 including 48, 163, 162, 181, 204, 244, 245, 247, 370, 405 
8 blaKPC including 1, 2, 3 
9 blaNDM including 1, 2, 3, 4, 5, 6, 7, 8 
10 blaVIM including 1, 2, 3 
Trimethoprim resistance determinants 
11 dfr including A1, A5/A14 
12 dfr including A12, A7/ A17 
Aminoglycoside resistance determinants 
13 aac(60) including Ib, Ic, Ig, Iy, Iq II, IIc and aac(60)-Ib-cr 
14 aadA including A1, A2, A3 
Fluoroquinolone resistance mutations 
15 gyrA including gyrA/Sa, gyrA/Ra, gyrKlebR/Sb 
16 KPparCc 
Controls 
 tuf Enterobacteriaceae, with Tm varying according to genus 
 SPIKE internal control 
 
a This assay was designed to detect point mutations in gyrA affecting Ser83 and Asp87 and associated with high-level ciprofloxacin 
resistance; these were distinguished by PCR products with different Tm values for E. coli only. 
b The assay was designed to identify Klebsiella spp. but not discriminate between resistant and susceptible types. 
c 
This assay was designed to identify fluoroquinolone resistant/susceptible Klebsiella spp. based on PCR product Tm. 
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specificity. WGS confirmed the presence of aadA1/A2/A3 in 7/8 PCR-
positive isolates; including three that were susceptible to streptomycin. 
The gyrA assay (Tables 1 and 2) amplified across the region encoding 
the mutations (Ser83 and Asp87) responsible for most high-level 
ciprofloxacin resistance, leading to a shift in the Tm of the resulting 
amplicon in E. coli. Thus, the Tm for the gyrA product of ciprofloxacin-
resistant E. coli (n " 10, identified as ‘gyrA/R’ by the assay) was between 
85C and 86C (mean 85.5C) but was between 86C and 87C (mean 86.5C) 
for ciprofloxacin-susceptible 
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Table 4. Comparison of results between the 8-plex MT-PCR panel and reference methods 
No. of samples with corresponding combinations of results (among 7 DNAs, 7 cultivated isolates and 7 urines) 
Gene sought by MT-
PCR (and found/not 
found): dfrA1 
dfrA5/ 
A14 
trimethoprim 
 
dfrA7/ 
A17 dfrA12 
no dfr 
gene 
found 
aadA1/ 
A2/A3 
streptomycin 
 
aadA1/A2/A3 
not found 
aac(6 
- 
0) 
Ib 
tobramycin 
 
aac(60)-
Ib not 
found 
 
ciprofloxacin 
 
gyrA/R gyrA/S gyrKlebR/S KPparC 
Total no. samples 
with indicated 
result 
4 6 8 3 0 8 13 14  7 10a 4a 7b 7b 
Of which: 
gene confirmed 
by sequencing; 
resistant to 
corresponding 
antibiotic 
3 5 7 3 – 4 – 13 – – – – – 
gene confirmed by 
sequencing; 
susceptible to 
corresponding 
antibiotic 
– – – – – 3 – – – – – – – 
resistant to corre- 
sponding antibioticc 
1 1 1 – – 1 9 1 – 10 – 6 6 
susceptible to corre- 
sponding antibioticc 
– – – – –  – 4 – 7d – 4 1 1 
Sensitivity   100%   35.7% 100%   100%  
Specificity   100%   57.1% 100%   100%  
a 
All E. coli. 
b 
All Klebsiella spp. 
c 
Phenotypic data available only. d 5/7 samples were sequenced 
but genes were not found. 
organisms (n " 4, identified as ‘gyrA/S’). The gyrA assay also identified 
K. pneumoniae, giving a product (gyrKlebR/S) with a Tm of 88C–89C 
(mean 88.5C), but did not distinguish ciprofloxacin resistance or 
susceptibility in this species. A gyrKlebR/S product was seen for all 7 
K. pneumoniae samples and for none of the 14 E. coli. The KPparC assay 
aimed to predict fluoroquinolone resistance in Klebsiella based on the 
Tm shift contingent on the Ser80 mutation but failed to do so, with 
identical products from all seven isolates irrespective of phenotypic 
ciprofloxacin resistance. 
16-Plex panel 
Seventy-four infected urines were tested with the 16-plex assay, selected 
based on phenotypic testing of the corresponding isolates. Identification 
of b-lactamase genes from these urines by MT-PCR was in good 
agreement with real-time PCR on the corresponding isolates, with 100% 
sensitivity and, according to the enzyme, 95.3%–100% specificity 
(Table 5), though without discrimination of whether blaTEM and blaSHV 
genes encoded classic, inhibitor-resistant or ESBL types. The 16-plex 
assay found dfrA1/A5/A7/A12 in 38/41 urines containing isolates 
resistant to trimethoprim and in 1/33 urines containing a 
trimethoprimsusceptible organism, giving sensitivity 92.7% and 
specificity 97%. aac(60)-Ib was detected in nine urines, though only eight 
of these contained bacteria resistant to tobramycin, giving 100% 
sensitivity and 98.5% specificity. aadA1/A2/A3 genes were detected in 
9/24 urines containing bacteria resistant to streptomycin, but also in 8/ 
50 urines containing streptomycin-susceptible bacteria, giving 
sensitivity 37.5% and specificity 86%. 
A gyrA/R product (Tm " 85.5C) was obtained from 25/28 urines 
containing ciprofloxacin-resistant E. coli whereas the gyrA/S (Tm " 
86.5C) product was obtained from 22/25 urines containing 
ciprofloxacin-susceptible E. coli. On this basis, the E. coli gyrA 
fluoroquinolone resistance assay was 89.3% sensitive and 100% specific 
for urines (Table 6). The gyrA/R and gyrA/S were not, however, E. coli 
specific: corresponding PCR products were also obtained from 15 urines 
containing other Enterobacteriaceae, including 3 Citrobacter freundii, 8 
Enterobacter spp., 2 Serratia marcescens, 1 Klebsiella oxytoca, 1 Proteus 
spp. and 1 with a Pseudomonas spp. Nevertheless, E. coli was 
distinguished from other Enterobacteriaceae, except Citrobacter spp. 
based on a lower Tm for the tuf product (83.5 versus 84.0C) (Figure 1). 
Assays for gyrA and parC were less discriminatory among other 
species. Thus: (i) a gyrKlebR/S product was obtained from all K. 
pneumoniae-containing urines (n" 5) but also from one containing S. 
marcescens and from two containing Pseudomonas spp.; and (ii) Tm 
values for tuf products did not distinguish among Enterobacteriaceae 
species in these cases. 
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Thirty-five cultivated isolates were also tested with the 16-plex assay, 
selected as phenotypically multiresistant or based on sequencing data. 
Detection of b-lactamase genes agreed perfectly 
with reference molecular methods, giving 100% sensitivity and 
specificity (Table 5). Dihydrofolate reductase genes dfrA1/A5/A7/A12 
were identified in 30/32 trimethoprim-resistant isolates, with sensitivity 
and specificity (93.7% and 100%, respectively) nearly identical to values 
for clinical urines. aac(60)-Ib was found in 22/24 isolates with 
phenotypic tobramycin resistance, whereas aadA was detected in 10/18 
streptomycin-resistant isolates and in 6/17 streptomycin-susceptible 
ones, a mismatch rate similar to that for urines, with sensitivity 55.7% 
and specificity 64.7%. The fluoroquinolone gyrA/R product (Tm " 85.5C) 
was generated from 9/10 ciprofloxacin-resistant E. coli isolates, whereas 
gyrA/S (Tm " 86.5C) was obtained from 6/7 ciprofloxacin-susceptible E. 
coli isolates, with 90% sensitivity and 100% specificity for prediction of 
ciprofloxacin resistance in the species (Table 6). gyrA/R and gyrA/S 
PCR products 
were also obtained from two Enterobacter spp. and one K. oxytoca, with 
no correlation to phenotypic ciprofloxacin resistance; nevertheless, as 
with urines, E. coli could be distinguished from other species by the Tm 
for the tuf product. The gyrKlebR/S PCR product was obtained from all 
K. pneumoniae isolates (n" 15) and one nonfermenter (93.8% 
sensitivity); resistant and susceptible profiles were not distinguished for 
K. pneumoniae. 
The KPparC product was obtained from 19 urines and 19 isolates 
containing or representing 2/3 Citrobacter spp., 9/10 Enterobacter spp., 
2/2 K. oxytoca, 20/20 K. pneumoniae, 3/3 Serratia spp., 1/1 Proteus spp. 
and 1/1 Acinetobacter, whereas no signal was seen for any of 66 E. coli 
or 3 Pseudomonas spp. There was no difference in the Tm (88.5C) for the 
KPparC product between susceptible and resistant isolates of any 
species. 
Table 5. Comparison of results between the 16-plex panel and reference methods 
 Clinical urines (n " 74) Isolates (n " 35) 
 
Resistance gene 16-plex, no. reference, no. sensitivity; 16-plex, no. reference, no. sensitivity; 
target positive positive specificity, % positive positive specificity, % 
b-Lactamase genes versus molecular reference genes detected by real-time PCR blaTEM 33 
31 100; 95 24 24 100; 100 
blaSHV 6 6 100; 100 16 16 100; 100 
blaCTX-M group 1 24 23 100; 98 18 18 100; 100 
blaCTX-M group 9 13 13 100; 100 4 4 100; 100 
blaCMY 9 9 100; 100 7 7 100; 100 
blaOXA-1 8 8 100; 100 18 18 100; 100 
blaOXA-48/181/244 – – – 7 7 100; 100 
blaKPC – – – 5 5 100; 100 
blaNDM – – – 10 10 100; 100 
blaVIM – – – 1 1 100; 100 
Trimethoprim gene versus phenotypic trimethoprim resistance 
dfrA1/A5/A7/A12 39 41 92.7; 97 30 32 93.7; 100 
Aminoglycoside genes versus phenotypic tobramycin and streptomycin resistance aac(60)-
Ib 9 8 100; 98 22 24 91.7; 100 
aadA1/A2/A3 9 24 37.5; 86 10 18 55.7; 64.7 
 
Figure 1. Melting ranges for gyrA and Enterobacteriaceae (tuf) genes in the High-Plex UTI assay as an aid to genus identification. 
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Discussion 
Rapid molecular identification of resistance genes in clinical samples 
could guide early therapy for UTIs, improving patient outcomes and 
antimicrobial stewardship. PCR has been widely employed to seek 
resistance genes in clinical samples, but mostly to support infection 
control rather than to guide therapy.11–17 We explored its potential to 
detect important enterobacterial resistance genes in clinical urines 
without culture. Two iterations of an MT-PCR assay were tested, 
expanding the number of resistance targets. Similar sensitivity and 
specificity was achieved for both urines and cultured bacteria, 
demonstrating proof of principle, although further validation of the 
assays directly on urine samples is recommended. 
Both assays sought four widespread trimethoprim determinants 
(dfrA1, dfrA5/14, dfrA7/A17 and dfrA12), two aminoglycoside 
resistance genes [aadA1/A2/A3 and aac(60)-Ib] and sequence variants of 
gyrA and parC, where mutations confer high-level fluoroquinolone 
resistance. The 16-plex panel additionally sought b-lactamase genes, 
including common penicillinases (blaTEM and blaSHV), inhibitor-resistant 
penicillinase (blaOXA-1), acquired ampC 
(blaCMY), ESBLs (blaCTX-M group 1 and blaCTX-M group 9) and 
carbapenemases (blaOXA-48, blaKPC, blaNDM and blaVIM). 
Despite including only the most prevalent dfr alleles, the tests were 
good predictors of trimethoprim resistance. With the 16-plex assay, dfr 
alleles were found in 68/73 urines and isolates with trimethoprim 
resistance: dfrA7/A17 predominated in E. coli and dfrA5/A14 in K. 
pneumoniae, as also found in Sweden.18 Negative results for some 
trimethoprim-resistant isolates are likely to reflect the presence of other 
unsought dfr determinants, e.g. dfrA8, dfrA9, dfrA24, dfrA25 and 
dfrA26,19–24 or mutations in chromosomal folA, although these are rare.14 
The 16-plex assay achieved 100% sensitivity and 95%–100% 
specificity for b-lactamase genes in both clinical urines and cultivated 
isolates. This performance, using urines directly, is comparable to that 
found by others using similar methodology on cultivated isolates. Singh 
et al.15 developed a multiplex real-time PCR assay to successfully detect 
10 b-lactamases, including ESBLs, AmpC and carbapenemases, by Tm 
analysis, as here. The diversity of allelic variants sought was greater than 
in our study, though blaCTX-M group 9 (a common ESBL group) was 
omitted. Chavada and Maley25 used MT-PCR, as here, to seek 12 b-
lactamase genes in cultivated Gram-negative isolates, achieving 95% 
sensitivity and 96.7% specificity, and Willemsen et al.26 evaluated a 
commercial real-time PCR (Check-MDR ESBL PCR) to seek blaCTX-M-
like along with ESBL-encoding alleles of blaTEM and blaSHV, which (unlike 
here) were discriminated from classic forms, achieving 98.9% sensitivity 
and 100% specificity against a reference microarray. 
Detection of aac(60)-Ib was reliable by both MT-PCR panels (100% 
sensitivity for the 8-plex and 91.7%–100% sensitivity for the 16-plex); 
the main limitations were: (i) that tobramycin resistance can be caused 
by other unsought aminoglycoside resistance determinants; (ii) that 
amikacin resistance is a variable correlate of aac(60)-Ib carriage, though 
EUCAST counsels against its use whenever aac(60) variants are present; 
and (iii) that resistance to gentamicin, the most-used aminoglycoside in 
the UK, is associated with other enzymes, not aac(60)-Ib. A 24-plex 
assay variant, in early development, aims to address these aspects by 
adding further aminoglycoside-modifying gene targets (not shown). 
Table 6. Detection of fluoroquinolone-relevant genes by the 16-plex panel in relation to bacterial species 
Samples (n " 109) gyrA/R 
Clinical urines ( 
 
gyrA/S 
n " 74) 
gyrKlebR/S KPparC 
 
Isolates (n " 35) 
 
gyrA/R gyrA/S gyrKlebR/S KPparC 
E. coli (n " 66) 
CIP R 25 3 – – 9 1 – – 
CIP S – 22 – – – 6 – – 
K. pneumoniae (n " 20) 
CIP R – – 4 4 – – 13 13 
CIP S – – 1 1 – – 2 2 
Non-Enterobacteriaceae (n " 4)a 
CIP R – – – – – – 1 1 
CIP S 1 – 2 – – – – – 
Other Enterobacteriaceae s 
CIP R 
pecies (n " 19)b 
 2 – 3 – – – – 
CIP S  8 1 11 1 2 – 3 
Sensitivity, % 89.3 62.5 – 90  93.8 – 
Specificity, % 100 – – 100  – – 
CIP, ciprofloxacin; R, resistant; S, susceptible. 
aAcinetobacter spp. (n " 1), Pseudomonas spp. (n " 3). bC. freundii (n " 3), Enterobacter spp. (n " 10), S. marcescens (n " 
3), K. oxytoca (n " 2), Proteus spp. (n " 1). 
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High-level fluoroquinolone resistance in Enterobacteriaceae is 
mainly via mutations in gyrA or parC.27 The 8- and 16-plex MTPCRs 
accurately predicted ciprofloxacin resistance for E. coli from the Tm of 
the gyrA product. With the 16-plex assay, 89.3% sensitivity and 100% 
specificity were achieved for prediction of resistance in E. coli in urine; 
however, resistance was not predictable for other Enterobacteriaceae, 
some of which also gave products for gyrA in the assay. Parallel rapid 
identification of the pathogen by other techniques, e.g. MALDI-TOF MS 
directly from urine,28–30 may be 
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prudent; alternatively detection of a low-Tm (83.5C) tuf product in the 
16-plex assay strongly predicted E. coli. 
In contrast to good concordance for dfr, b-lactamase genes, aac(60)-
Ib and E. coli gyrA, there was poor agreement between carriage of 
aadA1/A2/A3 and streptomycin resistance, with these adenyltransferase 
determinants variably present in both streptomycin-resistant and -
susceptible bacteria. Other mechanisms (e.g. strA/strB and aadA5) likely 
explain streptomycin resistance in aadA-negative isolates but, in 
addition, it is apparent that aadA is often carried without resistance, as 
noted also by others.31 This might be explained by (i) the aadA gene 
being well separated from its common promoter in the 50-conserved 
segment of integrons, leading to poor expression,32 or (ii) ‘gene 
silencing’.33 In practical terms this failure matters little, as streptomycin 
is not ordinarily used to treat UTIs. The simplest answer would be to 
remove the aadA target from the assay. 
Given the performance demonstrated here, the AusDiagnostics MT-
PCR tests have the potential for use in community clinics for the rapid 
(,3 h) investigation of UTIs, helping determine whether to treat with 
trimethoprim or ciprofloxacin rather than nitrofurantoin, which is 
currently favoured owing to a lower resistance rate, despite being 
inferior in tolerability, pharmacokinetics and efficacy. The patient’s 
midstream urine would be tested at the clinic visit and, if no dfr 
determinant is found, a prescription for trimethoprim would be 
electronically issued to a pharmacy for collection on the same day. If a 
trimethoprim resistance determinant is found, results for tuf and gyr 
would be reviewed and, if susceptible E. coli is predicted, ciprofloxacin 
would be prescribed. If resistance to both trimethoprim and 
ciprofloxacin is predicted, prescription would default to nitrofurantoin 
(or, possibly, pivmecillinam or fosfomycin). Assuming 25% 
trimethoprim resistance and 92.7% sensitivity/97% specificity for 
detection of resistance, as with the 16-plex panel, 72% of patients would 
receive trimethoprim and only 6% would do so inappropriately. This 
compares favourably with the previous maxim that trimethoprim (or co-
trimoxazole) could be used empirically in cystitis, up to a resistance rate 
of 15%– 20%,34 and to the present policy of preferring empirical 
nitrofurantoin, despite its limitations and a resistance rate of 6%.35 
For cUTI hospital admissions, or patients with hospital-acquired 
UTIs, the 16-plex assay could reasonably be used to distinguish patients: 
(i) with pathogens likely to be resistant to cephalosporins (i.e. with 
blaCTX-M or blaCMY or any carbapenemase gene); (ii) with pathogens 
likely to be resistant to penicillin/b-lactamase inhibitor combinations 
(with blaOXA-1, blaCMY or any carbapenemase); or (iii) with pathogens 
likely to be resistant to carbapenems (any carbapenemase). Detection of 
aac(60)-Ib should warn against use of tobramycin and amikacin. Such 
information, available within ,3 h, would reduce pressure to use 
carbapenems in patients developing sepsis, based on the suggestion that 
‘the patient has risk factors for ESBL producers’. The cost of the 
equipment is 30000 GBP and the cost per sample is 12GBP. 
Challenges remain. First, although sensitivity .90% was achieved for 
key resistances, the system does not detect rare determinants, reflecting 
limits on the number of targets that can and non-ESBL variants of blaTEM 
and blaSHV, though these are 10fold rarer than blaCTX-M ESBLs among 
urinary E. coli.36,37 Fourthly, the system does not provide guidance for 
all antibiotics: for example, it does not seek the major determinants of 
gentamicin or fosfomycin resistance, and the latter would be difficult 
given that most resistance is mutational. Lastly, MT-PCR cannot predict 
an MIC, and resistance to cephalosporins and carbapenems among 
Enterobacteriaceae depends not only on b-lactamase type but also on 
permeability and efflux traits.38,39 These limitations must be balanced 
against those of standard culture, which does not deliver a result until 48 
h after the urine is taken. If resistance is prevalent this means (i) that 
many patients are undertreated if a compromised agent is retained as 
empirical therapy or (ii) that an agent with limitations but little resistance 
(e.g. nitrofurantoin) or one that would ordinarily be reserved (e.g. 
ertapenem) becomes the standard of empirical care. This far-from-ideal 
situation is accepted only because ‘that’s how it has always been done’. 
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